According to Zacks, “Tabula Rasa HealthCare, Inc. is a provider of patient-specific, data-driven technology and solutions which enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The company’s cloud-based software applications including EireneRx and MedWise Advisor which provide solutions to payers, providers and other healthcare organizations. Tabula Rasa HealthCare, Inc. is based in NJ, United States. “
A number of other research firms also recently issued reports on TRHC. Stifel Nicolaus raised shares of Tabula Rasa HealthCare from a hold rating to a buy rating and increased their target price for the stock from $50.00 to $75.00 in a research report on Friday, August 30th. BidaskClub downgraded shares of Tabula Rasa HealthCare from a strong-buy rating to a buy rating in a research report on Wednesday, September 4th. Finally, ValuEngine raised shares of Tabula Rasa HealthCare from a buy rating to a strong-buy rating in a research report on Wednesday, September 4th. Three analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and an average target price of $80.43.
TRHC traded down $0.23 on Thursday, reaching $51.30. 139,666 shares of the company’s stock were exchanged, compared to its average volume of 272,348. The company’s 50 day moving average is $56.56 and its 200-day moving average is $53.58. The company has a market cap of $1.15 billion, a price-to-earnings ratio of 150.88 and a beta of 1.66. Tabula Rasa HealthCare has a twelve month low of $40.86 and a twelve month high of $83.37. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.90 and a current ratio of 1.97.
Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its earnings results on Thursday, August 8th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.29. The firm had revenue of $76.26 million during the quarter, compared to the consensus estimate of $70.40 million. Tabula Rasa HealthCare had a negative net margin of 7.09% and a positive return on equity of 3.63%. The company’s revenue was up 56.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.20 EPS. Sell-side analysts forecast that Tabula Rasa HealthCare will post -0.15 EPS for the current year.
In other Tabula Rasa HealthCare news, President Orsula V. Knowlton sold 8,000 shares of the stock in a transaction that occurred on Thursday, July 18th. The shares were sold at an average price of $54.85, for a total value of $438,800.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gordon Tunstall sold 1,000 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $62.64, for a total transaction of $62,640.00. The disclosure for this sale can be found here. Insiders sold 77,000 shares of company stock valued at $4,482,300 in the last ninety days. 11.80% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of TRHC. Aperio Group LLC acquired a new stake in Tabula Rasa HealthCare in the second quarter valued at approximately $39,000. First Mercantile Trust Co. boosted its stake in shares of Tabula Rasa HealthCare by 20.3% during the 2nd quarter. First Mercantile Trust Co. now owns 1,197 shares of the company’s stock valued at $60,000 after buying an additional 202 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of Tabula Rasa HealthCare during the 2nd quarter valued at approximately $82,000. Bank of Montreal Can boosted its stake in shares of Tabula Rasa HealthCare by 167.7% during the 2nd quarter. Bank of Montreal Can now owns 2,605 shares of the company’s stock valued at $129,000 after buying an additional 1,632 shares during the last quarter. Finally, Neuburgh Advisers LLC boosted its stake in shares of Tabula Rasa HealthCare by 18.2% during the 2nd quarter. Neuburgh Advisers LLC now owns 2,704 shares of the company’s stock valued at $135,000 after buying an additional 416 shares during the last quarter. 98.75% of the stock is owned by institutional investors.
Tabula Rasa HealthCare Company Profile
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.
Featured Article: Do back-end load funds outperform no-load funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.